389 related articles for article (PubMed ID: 19303657)
1. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
3. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
[TBL] [Abstract][Full Text] [Related]
6. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
7. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
Liaw YF
Semin Liver Dis; 2005; 25 Suppl 1():40-7. PubMed ID: 16103980
[TBL] [Abstract][Full Text] [Related]
8. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
[TBL] [Abstract][Full Text] [Related]
9. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
10. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment.
Sherman M
J Hepatol; 2009 May; 50(5):854-6. PubMed ID: 19303162
[No Abstract] [Full Text] [Related]
11. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region.
Amarapurkar D; Han KH; Chan HL; Ueno Y;
J Gastroenterol Hepatol; 2009 Jun; 24(6):955-61. PubMed ID: 19383082
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Kim BK; Han KH; Ahn SH
Oncology; 2011; 81 Suppl 1():41-9. PubMed ID: 22212935
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
15. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
17. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
19. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk.
Chang Y; Lairson DR; Chan W; Lu SN; Aoki N
J Eval Clin Pract; 2011 Apr; 17(2):261-7. PubMed ID: 20874834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]